Lung cancer patients gain early access to promising new drug

NCT ID NCT04830202

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program provides early access to telisotuzumab vedotin, an investigational drug, for eligible people with non-small cell lung cancer who have no other treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is given by intravenous infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: telisotuzumab vedotin (ABBV-399)
What this could lead to: If this drug works, it could offer a new treatment option for people with non-small cell lung cancer who have no other suitable therapies.
What could go wrong: This is an expanded access program, not a formal trial, so data on effectiveness and safety are limited. The drug is investigational and may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.